The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel).
 
Derrick Tao
No Relationships to Disclose
 
Reham Abdel-Wahab
No Relationships to Disclose
 
Ruitao Lin
Consulting or Advisory Role - ITM Oncologics; Lilly; Merck Sharp & Dohme, LLC; Monte Rosa Therapeutics
 
May Daher
Research Funding - Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Institutional financial conflict of interest with Takeda Pharmaceutical for the licensing of the technology related to CAR-NK cell research. MD Anderson has implemented an Institutional Conflict of Interest Management and Monitoring Plan to manage and mon
 
Bin Liu
No Relationships to Disclose
 
Rafet Basar
Research Funding - Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Institutional financial conflict of interest with Takeda Pharmaceutical for the licensing of the technology related to CAR NK cells research. MD Anderson has implemented an Institutional Conflict of Interest Management and Monitoring Plan to manage and mo
 
Elizabeth Shpall
Honoraria - Bayer
Consulting or Advisory Role - Adaptimmune; AXIO Research; Celaid Therapeutics; Fibrobiologics; Navan; NY Blood Center
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics; Syena; Takeda
Travel, Accommodations, Expenses - Magenta Therapeutics; Novartis
 
Katy Rezvani
Consulting or Advisory Role - Avenge Bio; Bayer; Bit Bio Limited; Caribou Biosciences; GEMoaB; Innate Pharma; NAVAN Technologies; oNKo Innate; Replay Holdings; Shinobi Therapeutics; The Alliance for Cancer Gene Therapy ACGT; Virogen
Research Funding - Affimed Therapeutics; Pharmacyclics; Takeda
Patents, Royalties, Other Intellectual Property - License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy.; License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy. (Inst); License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy; License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy (Inst); Patent on generation of BKV CTLs for the treatment of HC or PML; Patent on generation of CAR NK cells
 
Adi Diab
Honoraria - Cullinan Oncology (Inst); CureVac; CytomX Therapeutics; Genesis Therapeutics; Idera (Inst); Lytix Biopharma (Inst); Memgen; Nektar (Inst); Pfizer; Regeneron; Teva
Consulting or Advisory Role - Celgene; CureVac; CytomX Therapeutics; Idera; Memgen therapeutics; Nektar; Pfizer (Inst); Regeneron
Research Funding - Apexigen (Inst); Celgene (Inst); Cullinan Oncology (Inst); Cullinan Oncology (Inst); Idera (Inst); Lytix Biopharma (Inst); Lytix Biopharma (Inst); Nektar (Inst); Pfizer (Inst)